Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.
Follow VTRS
Viatris Inc. (VTRS) P/E ratio
Viatris Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 762× (February 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 228× | 3,322.99% |
| FY2022 | 6.7× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 670× | 1,562.77% |
| FY2018 | 40.3× | 22.44% |
| FY2017 | 32.9× | (23.43%) |
| FY2016 | 43.0× | 39.10% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | n/m |
| VTRS Viatris Inc. | n/m |
| ZTS Zoetis Inc. compare | 13.0× |
| UTHR United Therapeutics Corporation compare | 17.6× |
| NBIX Neurocrine Biosciences, Inc. compare | 19.2× |
| HLN Haleon PLC Sponsored ADR compare | 22.6× |
| TAK Takeda Pharmaceutical Co. compare | 29.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 32.9× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 65.9× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement